The 2 analysts offering 12-month price forecasts for Bellerophon Therapeutics Inc have a median target of 28.00, with a high estimate of 30.00 and a low estimate of 26.00. The median estimate represents a +573.08% increase from the last price of 4.16.
The current consensus among 2 polled investment analysts is to Buy stock in Bellerophon Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.62
Reporting Date Aug 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.